{"entity":{"id":"nct06244992","kind":"trial","name":"PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of PTT-936 in advanced solid tumours, run by Pyrotech Therapeutics, Inc., now recruiting.","summary":"PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06244992 by Pyrotech Therapeutics, Inc., with 68 participants planned, started 2024-01-26 and due to reach its primary completion in 2027-09-30. Interventions recorded: PTT-936 and Combination of PTT-936 and anti-PD-1/L1 therapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06244992","url":"https://clinicaltrials.gov/study/NCT06244992"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06244992","phase":"1/2","setting":"A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination With Anti-PD-1/L1 in Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"Pyrotech Therapeutics, Inc.","enrolled":68,"outcomes":[]},"route":"/trials/nct06244992/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}